CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Olaparib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04076579
NCT04076579Phase 2Completed
CompareCT.gov

Phase II Multi-Center Trial of Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

University of Michigan Rogel Cancer Center·interventional·Posted Sep 3, 2019·Updated Aug 29, 2025

In Brief

A Phase 2 clinical trial evaluating Olaparib and Trabectedin for Sarcoma and Sarcoma Metastatic. Completed, enrolled 29 participants across 1 site.

Detailed Summary

This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing cells, stopping them from dividing or stopping them from spreading. Olaparib may stop the growth of tumor cells by blocking pathways responsible for repairing damaged cells. Giving trabectedin and olaparib may shrink or stop the tumor from growing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Sarcoma Metastatic
CountriesUnited States
CollaboratorsJanssen Scientific Affairs, LLC, AstraZeneca

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 3, 2019
Enrollment StartMar 17, 2020
Primary CompletionJan 30, 2023
Study CompletionSep 26, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.8 years ago

Interventions

Olaparibdrug

Olaparib taken by mouth twice daily

Trabectedindrug

Trabectedin administered intravenously (IV) every 21 days